Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: umbro who wrote (12004)	7/29/1998 3:25:00 PM
From: Marconi	Read Replies (1) \| Respond to of 164684

Hello Mr. Funck: Excellent points and issues about AMZN selling pharmaceuticals. Two separate thoughts: 1)AMZN management may be thinking it IS them--not external forces relying on 'new' economics--which most accept will revert to old economics--the reality of returns. 2)Book selling is a relatively low margin business with the primary takeouts between seller and customer directly. Pharmaceuticals decouple the buying and selling decision from the customer, with the primary takeouts being intermediaries who receive no critical scrutiny on average from the customer. These are two entirely different business processes. Pharms would be a major diversification for AMZN, not a synergistic overhead defraying, counter-cyclical (to books) conglomeration of business for AMZN. Me-thinks batty management has too much play money baiting, batting, and battering proper business development thought. AMZN's real problem is to find a profitable business while having access to much OPM (other people's money) with prospects of a durable competitive advantage through excellent management. Best regards, m